Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 19/20 | 0.61 |
| ▸ | DHFR | P00374 | 2/20 | 0.61 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.61 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.61 |
| ▸ | GART | P22102 | 1/20 | 0.61 |
| ▸ | ATIC | P31939 | 1/20 | 0.61 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.61 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.61 |
| ▸ | FRK | P42685 | 1/20 | 0.61 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16582197 | 0.89 | TYMS (0.70) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL12905188 | 0.89 | TYMS (0.59) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL12905859 | 0.89 | TYMS (0.59) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL20908952 | 0.86 | TYMS (0.56) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL20386836 | 0.86 | TYMS (0.56) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL13524779 | 0.86 | TYMS (0.67) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL26019440 | 0.85 | TYMS (0.55) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL23117778 | 0.85 | TYMS (0.69) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL12264580 | 0.85 | TYMS (0.69) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL23117779 | 0.85 | TYMS (0.69) | TYMSDHFRFOLR2FOLR1GART |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150899-A1 | CONJUGATES OF CHEMOTHERAPY AGENTS AND TISSUE-BINDING SMALL MOLECULES, COMPOSITIONS AND METHODS THEREOF | CANWELL BIOTECH LIMITED (CN) | 2023-08-17 | — | — | WO | disclosed |
| US-20230201203-A1 | METHODS OF TREATMENT USING ANTIFOLATES AND PHARMACEUTICAL FORMULATIONS COMPRISING ANTIFOLATES | EMPHASCIENCE, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2022150721-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201203-A1 | METHODS OF TREATMENT USING ANTIFOLATES AND PHARMACEUTICAL FORMULATIONS COMPRISING ANTIFOLATES | DHFR, MTHFD1, OAT | TYMS 18/4885DHFR 1/4885FOLR2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.